NEW YORK, Feb. 10 (GenomeWeb News) - Nanogen plans to acquire Syn X Pharma in an all-stock transaction, the company said today.

 

The transaction is valued at approximately CA$16.3 million ($12.3 million). Under the agreement, Nanogen will offer common shares to holders of Syn X common shares in a stock-for-stock exchange.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.